Category Archives: Genetic Engineering

Mankind #39;s Creation from Alien Genetic Engineering Full Length Documentary
Mankind #39;s Creation from Alien Genetic Engineering Full Length Documentary documentary, history, discovery, world, wild life, full length, nature, animal, mys...

By: Discovery TV

See the original post:
Mankind's Creation from Alien Genetic Engineering Full Length Documentary - Video

PUBLIC RELEASE DATE:

9-Oct-2014

Contact: Kathryn Ryan kryan@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News @LiebertOnline

New Rochelle, NY, October 9, 2014Laser Solid Forming (LSF) is an innovative method for direct fabrication of metallic components in additive manufacturing. Renowned researchers Weidong Huang and Lin Xin, from China's Northwestern Polytechnical University, Shaanxi, describe their progress and applications with LSF technology and the excellent mechanical properties of the metallic parts produced in a Review article in 3D Printing and Additive Manufacturing, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the 3D Printing and Additive Manufacturing website until November 9, 2014. In the article "Research Progress in Laser Solid Forming of High Performance Metallic Components at the State Key Laboratory of Solidification Processing of China," the authors review research advances toward the goal of developing LSFan additive manufacturing technique that uses laser cladding with synchronously feeding metal powdersfor obtaining fully dense metal parts with mechanical properties similar to those produced by casting or forging.

"Additive manufacturing technologies have a global reach that is impacting the manufacturing landscape worldwide, and it is critical that both technology developers and users across the planet keep abreast of each other's progress," says Editor-in-Chief Hod Lipson, PhD, Professor at Cornell University's Sibley School of Mechanical and Aerospace Engineering, Ithaca, NY.

###

About the Journal

3D Printing and Additive Manufacturing is a peer-reviewed journal published quarterly online with Open Access options and in print. Spearheaded by Hod Lipson, PhD, Director of Cornell University's Creative Machines Lab at the Sibley School of Mechanical and Aerospace Engineering, the Journal explores emerging challenges and opportunities ranging from new developments of processes and materials, to new simulation and design tools, and informative applications and case studies. Spanning a broad array of disciplines focusing on novel 3D printing and rapid prototyping technologies, policies, and innovations, the Journal brings together the community to address the challenges and discover new breakthroughs and trends living within this groundbreaking technology. Tables of content and a sample issue may be viewed on the 3D Printing and Additive Manufacturing website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative medical and biomedical peer-reviewed journals, including Big Data, Soft Robotics, New Space, Tissue Engineering, and Stem Cells and Development. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's more than 80 journals, newsmagazines, and books is available on the Mary Ann Liebert, Inc., publishers website.

More:
New advances in additive manufacturing using laser solid forming to produce metallic parts

PUBLIC RELEASE DATE:

9-Oct-2014

Contact: Kathryn Ryan kryan@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News @LiebertOnline

New Rochelle, NY, October 9, 2014Excessive and often lethal blood levels of bilirubin can result from mutations in a single gene that are the cause of the metabolic disease known as Crigler-Najjar syndrome type 1 (CNS1). A new gene therapy approach to correcting this metabolic error achieved significant, long-lasting reductions in bilirubin levels in a mouse model of CNS1 and is described in an Open Access article in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the Human Gene Therapy website at http://online.liebertpub.com/doi/full/10.1089/hum.2013.233.

In "Life-Long Correction of Hyperbilirubinemia with a Neonatal Liver-Specific AAV-Mediated Gene Transfer in a Lethal Mouse Model of CriglerNajjar Syndrome," Giulia Bortolussi and coauthors from the International Centre for Genetic Engineering and Biotechnology; Centro Studi Fegato, Fondazione Italiana Fegato; and University of Trieste (Trieste, Italy) and Charles University (Prague, Czech Republic), present details of the adeno-associated virus (AAV)-mediated gene therapy approach they used to correct the metabolic disorder that causes hyperbilirubinemia in CNS1. The researchers reported 70-80% reductions in plasma bilirubin levels early on among treated animals, with about 50% reductions maintained throughout the study. The authors compared the effectiveness of two delivery strategies: targeting the therapeutic gene directly to the liver or, preferably, to skeletal muscle. They discuss the implications of the different results they obtained with each approach.

"CNS1 is an outstanding model for in vivo gene therapy with easily measured and clinically relevant metabolic endpoints," says James M. Wilson, MD, PhD, Editor-in-Chief of Human Gene Therapy, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.

###

About the Journal

Human Gene Therapy, the Official Journal of the European Society of Gene and Cell Therapy, British Society for Gene and Cell Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies, is an authoritative peer-reviewed journal published monthly in print and online. Human Gene Therapy presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Its sister journals, Human Gene Therapy Methods, published bimonthly, focuses on the application of gene therapy to product testing and development, and Human Gene Therapy Clinical Development, published quarterly, features data relevant to the regulatory review and commercial development of cell and gene therapy products. Tables of contents and sample issues for all three publications may be viewed on the Human Gene Therapy website at http://www.liebertpub.com/hgt.

About the Publisher

See the article here:
Long-term treatment success using gene therapy to correct a lethal metabolic disorder

A Short Introduction to Genetic Engineering 2

By: QuantelOnline

Visit link:
A Short Introduction to Genetic Engineering 2 - Video

Salmon Genetic Engineering
Derp.

By: Brandon Dodd

More here:
Salmon Genetic Engineering - Video

Genetic Engineering, Biofertilisation, Soil Quality And Organic Farming
Book Summary: Genetic Engineering, Biofertilisation, Soil Quality And Organic Farming ISBN: 9789048187409 Share the book of your favorite author. See more http://www.bluecoffeeandbooks.com...

By: Blue Coffee And Books

See the original post here:
Genetic Engineering, Biofertilisation, Soil Quality And Organic Farming - Video

GenapSys has appointed Mark Pratt as vice president of product development. Most recently, Pratt was senior director of accuracy R&D at Personalis. Before that, he served at Illumina, where he was responsible for engineering research, including holding leadership positions in the development of the HiSeq and MiSeq systems.

The Personalized Medicine Coalition announced that Daryl Pritchard will be its new VP of science policy, in charge of promoting the organization's science-related policies and of raising awareness of precision healthcare issues among policymakers, providers, and patients. Before joining PMC, Pritchard was director of policy research at the National Pharmaceutical Council; director of research programs advocacy and personalized medicine at the Biotechnology Industry Organization; and the director of government affairs for the American Association for Dental Research.

Nabsys has appointed Steve Lombardi to president, CEO, and to its board of directors. Previously, he was CEO of Real Time Genomics, and before that he was CEO of Helicos BioSciences. He has also served as senior vice president of Affymetrix and vice president of genetic analysis at Applied Biosystems.

Roche said this week that Arthur Levinson has resigned from its board of directors, effective immediately. The drugmaker said Levinson, who was chairman and CEO at Genentech from 1999 to 2014, made the decision to avoid any conflict with his post as CEO at Calico, a Google-backed startup. Levinson has served on Roche's board since 2010.

Sanford Burnham Medical Research Institute said this week it has named Perry Nisen as its CEO and as holder of the Donald Bren Chief Executive Chair. Nisen joins Sanford Burnham from GlaxoSmithKline, where he was senior VP of science and innovation.

Originally posted here:
Genetic Technologies Reports 'Consistent' Q1 BREVAGen Volume, Launches Second Generation Dx

PUBLIC RELEASE DATE:

7-Oct-2014

Contact: Kathryn Ryan kryan@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News @LiebertOnline

New Rochelle, NY, October 7, 2014Low sexual desire is common among both pre- and post-menopausal women. It can cause personal distress, harm relationships, and have a negative impact on body image and self confidence. Yet few women seek medical care for this condition, and the reasons are explored in a timely article in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Women's Health website at http://online.liebertpub.com/doi/full/10.1089/jwh.2014.4743 until November 7, 2014.

In the article "Attitudinal Survey of Women Living with Low Sexual Desire," Sheryl A. Kingsberg, PhD, Case Western Reserve University School of Medicine (Cleveland, OH), presents the results of a survey of women's attitudes toward low sexual desire and their awareness of its treatability as a medical condition. Dr. Kingsberg found that more than one-quarter of premenopausal and one-third of post-menopausal women were very dissatisfied with their current level of sexual desire. Most had not discussed their low sexual desire with their health care providers because they felt uncomfortable or embarrassed or were not aware that it is a treatable condition.

"Given the prevalence of low sexual desire in women and the important role that sexual function plays in women's lives, healthcare providers should recognize female sexual function as an integral part of health and well-being," says Susan G. Kornstein, MD, Editor-in-Chief of Journal of Women's Health, Executive Director of the Virginia Commonwealth University Institute for Women's Health, Richmond, VA, and President of the Academy of Women's Health.

###

About the Journal

Journal of Women's Health, published monthly, is a core multidisciplinary journal dedicated to the diseases and conditions that hold greater risk for or are more prevalent among women, as well as diseases that present differently in women. The Journal covers the latest advances and clinical applications of new diagnostic procedures and therapeutic protocols for the prevention and management of women's healthcare issues. Complete tables of content and a sample issue may be viewed on the Journal of Women's Health website at http://www.liebertpub.com/jwh. Journal of Women's Health is the official journal of the Academy of Women's Health and the Society for Women's Health Research.

About the Society

Read more:
Why do women struggling with low sexual desire not seek treatment?

Nicotine Removal Genetic Engineering (1986)
Philip Morris USA video.

By: Dick Clark Obama VHS Returns Logos Is Back.

Originally posted here:
Nicotine Removal Genetic Engineering (1986) - Video

PUBLIC RELEASE DATE:

6-Oct-2014

Contact: Kathryn Ryan kryan@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News @LiebertOnline

New Rochelle, NY, October 6, 2014Self-management of diabetes, including medication, nutrition, and lifestyle strategies, is essential for optimal glycemic control and minimizing complications of the disease. Education to teach and improve self-management skills is critical for success and, when delivered via the Internet, can lead to better glycemic control and enhanced diabetes knowledge compared to usual care, according to a Review article in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the DTT website at http://online.liebertpub.com/doi/full/10.1089/dia.2014.0155 until November 6, 2014.

Katherine Pereira, DNP, Beth Phillips, MSN, Constance Johnson, PhD, and Allison Vorderstrasse DNSc, Duke University School of Nursing (Durham, NC), review various methods of delivering diabetes education via the Internet and compare their effectiveness in improving diabetes-related outcomes. In the article "Internet Delivered Diabetes Self-Management Education: A Review" the authors describe some of the benefits of this method of educating patients, including ease of access and the ability to self-pace through the materials.

"With the increasing prevalence of diabetes globally and a decreasing number of available healthcare providers, alternative approaches and better education in self-management are necessary to improve diabetes outcomes," says DTT Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver. "This study evaluates the role of Internet-based self-management in diabetes-related outcomes."

###

About the Journal

Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of contents and a free sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website at http://www.liebertpub.com/DTT. DTT is the official journal of the Advanced Technologies & Treatments for Diabetes (ATTD) Conference.

About ATTD

Continued here:
Is internet-based diabetes self-management education beneficial?